1. He, J.H.#; Zhang, W.L.#; Zhou, X.J.; Xu, F.F.; Zou, J.H.; Zhang, Q.Q; Zhao, Y; He, H.L.; Yang, H.*; Liu, J.P.* Reactive oxygen species (ROS)-responsive size-reducible nanoassemblies for deeper atherosclerotic plaque penetration and enhanced macrophage-targeted drug delivery. Bioactive Materials. 2023; 19: 115-126. (IF: 16.874)
2. Jiahui Zou, Jianhua He, Xiaobo Wang, Yajie Wang, Chenchen Wu, Mengya Shi, Hulin Jiang, Zimei Wu, Jianping Liu, Wenli Zhang*. Glycoprotein Ib-regulated micro platelet ghost for biosafe distribution and photothermal oncotherapy. Journal of Controlled Release. 2022，351: 341-346. (IF: 11.467)
3. Zi, Y.X.; Yang, K.Y.; He, J.H.; Wu, Z.M.*; Liu, J.P.*; Zhang, W.L.* Strategies to enhance drug delivery to solid tumors by harnessing the EPR effects and alternative targeting mechanisms. Advanced Drug Delivery Reviews. 2022; 188: 114449. (IF: 17.873)
4. Wang, Y.Y.; Gao, H.; Huang, X.Y.; Chen, Z.A.; Kang, P.Y.; Zhou, Y.Y.; Qin, D.H.; Zhang, W.L.*; Liu J.P.* Cyclodextrin boostered-high density lipoprotein for antiatherosclerosis by regulating cholesterol efflux and efferocytosis. Carbohydrate Polymers. 2022; 292: 119632. (IF: 10.723)
5. Wang, X.B.; Zhang, W.L.* The Janus of Protein Corona on nanoparticles for tumor targeting, immunotherapy and diagnosis. Journal of Controlled Release. 2022; 345: 832-850. (IF: 11.467)
6. Jin, Y.; Wu Z.M.; Wu C.C; Zi, Y.X.; Chu, X.Y.; Liu J.P.*; Zhang, W.L.* Size-adaptable and ligand (biotin)-sheddable nanocarriers equipped with avidin scavenging technology for deep tumor penetration and reduced toxicity. Journal of Controlled Release. 2020; 320(10): 142-158. (IF: 9.770)
7. Zhang, W.L.; Wang, G.J.; Esther See; John P. Shaw; Bruce C. Baguley; Liu J.P.; Satya Amirapu; Wu, Z.M.* Post-insertion of poloxamer 188 strengthened liposomal membrane and reduced drug irritancy and in vivo precipitation, superior to PEGylation. Journal of Controlled Release. 2015; 203: 161-169. (IF: 7.877)
8. Zhang, W.L.#; He, H.L.#; Liu J.P*; Wang, J.; Zhang, S.Y.; Zhang, S.S.; Wu, Z.M. Pharmacokinetics and atherosclerotic lesions targeting effects of tanshinone IIA discoidal and spherical biomimetic high density lipoproteins. Biomaterials. 2013; 34(1): 306-319. (IF: 8.806)
1. Smart drug delivery system to remedy EPR effect for tumor.
2. Targeting drug delivery system to deal with drug-resistant bacteria.
3. Anti-atherosclerosis biomimetic drug delivery system.
4. Functional cosmetics for problematic skin care.
1. Research Projects
(1) 2019.1-2022. 12, Six Talent Peak Project in Jiangsu Province. Application of biotin-avidin system and targeting-off targeting technology in enhancing carrier safety and tumor penetration (No. SWYY-106). Appointment: principal investigator.
(2) 2016.1-2018.12. Natural Science Foundation of China. Construction of self-eliminated drug delivery system in non-targeting tissues with transformation-triggered drug release and alteration effect in tumor microenvironment and its mechanism of tumor penetration (No.81503005), Appointment: principal investigator.
(3) 2014.6-2017.6. Natural Science Foundation of Jiangsu Province. Multi-stage released drug delivery system with tumor-targeted and tumor-penetrated function (No. BK20140669). Appointment: principal investigator.
(4) 2013.1-2015.12. Specialized Research Fund for the Doctoral Program of Higher Education of China. Constitution of lovastatin-loaded reconstituted high density lipoproteins and PKPB model (No. 20120096120005). Appointment: principal investigator.
(5) 2018.1-2021.12. Natural Science Foundation of China. Constitution of recombinant high density lipoprotein drug delivery system based on the regulation of hemodynamics and microenvironment in atherosclerotic lesions and the study of drug delivery mechanism. (No.81773669), Appointment: main participant.
(6) 2013.1-2016.12. Natural Science Foundation of China. Constitution of high density lipoprotein drug delivery system and study of its allosteric dynamics and relationship between dose and efficacy (No.81273466), Appointment: main participant.
(7) 2012.3-2015.3. International scientific and technological collaboration project. Drug delivery for cancer chemotherapy to prevent phlebitis (No. 2011DFG33380), Appointment: participant.
(8) 2015.1-2018.12. Natural Science Foundation of China. Construction of a multivariate drug release system based on the deconvolution principle and chronological delivery synchronization of the main components of salvia miltiorrhiza and study on its quantitative integration (No.81473151), Appointment: participant.
(9) 2015.1-2017.12. Study on intracellular biopharmaceutics and pharmacokinetics pharmacodynamics of albumin nanodrug delivery system (No.81402878), Appointment: participant.
2. Academic Awards
(1) 2021, Jiangsu Province Micro Course Competition, the third Award, first place.
(2) 2020, Jiangsu Province Micro Course Competition, the second Award, first place.
(3) 2020, Jiangsu Province Graduate Student Innovation and Entrepreneurship Competition, Best Creative Award Instructor Award, second place.
(4) 2017, Excellent Academic Paper Award in natural science, Nanjing, third prize, first place.
(5) 2015, Excellent Academic Paper Award in natural science, Nanjing, third prize, first place.
3. Representative Research Achievements
(1) Smart drug delivery system to remedy EPR effect for tumor.
Despite the tremendous theranostics potential of nano-scale drug delivery system (NDDS) in oncology field, their tumor-targeting efficiency and safety remain major challenges due to their proneness of off-target accumulation through widespread vascular endothelial gaps (up to 1 μm). To address this problem, micro-nano sized cellular platelet “ghosts” DDS and avidin scavenging technology were employed to form a hierarchical biosafe system to reduce normal tissue interception and enhance tumor targeting drug delivery.
(2) Functional cosmetics for problematic skin care.
Multiple skin functional barrier including physical, microbial and immune barriers were repaired using functional cosmetics to deal with sensitive or chloasma skin. These functional cosmetics were developed with advanced skin penetration technology/preservative-free and green formula.
1. He, J.H.#; Zhang, W.L.#; Zhou, X.J.; Xu, F.F.; Zou, J.H.; Zhang, Q.Q; Zhao, Y; He, H.L.; Yang, H.*; Liu, J.P.* Reactive oxygen species (ROS)-responsive size-reducible nanoassemblies for deeper atherosclerotic plaque penetration and enhanced macrophage-targeted drug delivery. Bioactive Materials. 2023; 19: 115-126. (IF: 16.874)
2. Jiahui Zou, Jianhua He, Xiaobo Wang, Yajie Wang, Chenchen Wu, Mengya Shi, Hulin Jiang, Zimei Wu, Jianping Liu, Wenli Zhang*. Glycoprotein Ib-regulated micro platelet ghost for biosafe distribution and photothermal oncotherapy. Journal of Controlled Release. 2022，351: 341-346. (IF: 11.467)
3. Zi, Y.X.; Yang, K.Y.; He, J.H.; Wu, Z.M.*; Liu, J.P.*; Zhang, W.L.* Strategies to enhance drug delivery to solid tumors by harnessing the EPR effects and alternative targeting mechanisms. Advanced Drug Delivery Reviews. 2022; 188: 114449. (IF: 17.873)
4. Wang, Y.Y.; Gao, H.; Huang, X.Y.; Chen, Z.A.; Kang, P.Y.; Zhou, Y.Y.; Qin, D.H.; Zhang, W.L.*; Liu J.P.* Cyclodextrin boostered-high density lipoprotein for antiatherosclerosis by regulating cholesterol efflux and efferocytosis. Carbohydrate Polymers. 2022; 292: 119632. (IF: 10.723)
5. Wang, X.B.; Zhang, W.L.* The Janus of Protein Corona on nanoparticles for tumor targeting, immunotherapy and diagnosis. Journal of Controlled Release. 2022; 345: 832-850. (IF: 11.467)
6. Jin, Y.; Wu Z.M.; Wu C.C; Zi, Y.X.; Chu, X.Y.; Liu J.P.*; Zhang, W.L.* Size-adaptable and ligand (biotin)-sheddable nanocarriers equipped with avidin scavenging technology for deep tumor penetration and reduced toxicity. Journal of Controlled Release. 2020; 320(10): 142-158. (IF: 9.770)
7. Zhang, W.L.; Wang, G.J.; Esther See; John P. Shaw; Bruce C. Baguley; Liu J.P.; Satya Amirapu; Wu, Z.M.* Post-insertion of poloxamer 188 strengthened liposomal membrane and reduced drug irritancy and in vivo precipitation, superior to PEGylation. Journal of Controlled Release. 2015; 203: 161-169. (IF: 7.877)
8. Zhang, W.L.#; He, H.L.#; Liu J.P*; Wang, J.; Zhang, S.Y.; Zhang, S.S.; Wu, Z.M. Pharmacokinetics and atherosclerotic lesions targeting effects of tanshinone IIA discoidal and spherical biomimetic high density lipoproteins. Biomaterials. 2013; 34(1): 306-319. (IF: 8.806)
(1) Research team
Professor Jianping Liu; Associate Professor Wenli Zhang; Associate Professor Wenting Song
(2) Doctoral student
Kaiyun Yang (Grade 2021)
(3) Master student
Yajie Wang (Grade 2020); Cunhui Zhai (Grade 2020); Xinya Huang (Grade 2020); Huimin Ge (Grade 2020); Xuanbo Liu (Grade 2021); Yan Ji (Grade 2021); Li Huang (Grade 2021); Xinqiuyue Wang (Grade 2021); Jiajia Su (Grade 2022); Han Zhou (Grade 2022); Jia Hua (Grade 2022); Weixin Zhong (Grade 2022);Ying Zhu (Grade 2022)
